GLP1 Tracker: Lilly continues to outgrow Novo- analyst
Bernstein analysts told investors in a note Tuesday that Eli Lilly (NYSE:LLY) is gaining ground in the GLP-1 market, edging closer to market share parity with Novo Nordisk (NYSE:NVO).
Over half of adults are predicted to be overweight by 2050. Here's why weight-loss drugs aren't a cure
Over half of all adults — and a third of children and young adults — around the world are expected to be overweight or obese ...
South African watchdog probes Novo Nordisk and Sanofi over insulin
South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...